195 related articles for article (PubMed ID: 21723355)
1. An alternative renewable source of squalene for use in emulsion adjuvants.
Brito LA; Chan M; Baudner B; Gallorini S; Santos G; O'Hagan DT; Singh M
Vaccine; 2011 Aug; 29(37):6262-8. PubMed ID: 21723355
[TBL] [Abstract][Full Text] [Related]
2. MF59 and Pam3CSK4 boost adaptive responses to influenza subunit vaccine through an IFN type I-independent mechanism of action.
Caproni E; Tritto E; Cortese M; Muzzi A; Mosca F; Monaci E; Baudner B; Seubert A; De Gregorio E
J Immunol; 2012 Apr; 188(7):3088-98. PubMed ID: 22351935
[TBL] [Abstract][Full Text] [Related]
3. A novel oil-in-water emulsion as a potential adjuvant for influenza vaccine: development, characterization, stability and in vivo evaluation.
Deng J; Cai W; Jin F
Int J Pharm; 2014 Jul; 468(1-2):187-95. PubMed ID: 24704309
[TBL] [Abstract][Full Text] [Related]
4. Combination adjuvants for the induction of potent, long-lasting antibody and T-cell responses to influenza vaccine in mice.
Wack A; Baudner BC; Hilbert AK; Manini I; Nuti S; Tavarini S; Scheffczik H; Ugozzoli M; Singh M; Kazzaz J; Montomoli E; Del Giudice G; Rappuoli R; O'Hagan DT
Vaccine; 2008 Jan; 26(4):552-61. PubMed ID: 18162266
[TBL] [Abstract][Full Text] [Related]
5. Systemic cytokine profiles in BALB/c mice immunized with trivalent influenza vaccine containing MF59 oil emulsion and other advanced adjuvants.
Valensi JP; Carlson JR; Van Nest GA
J Immunol; 1994 Nov; 153(9):4029-39. PubMed ID: 7930610
[TBL] [Abstract][Full Text] [Related]
6. MF59-adjuvanted influenza vaccine (FLUAD) in children: safety and immunogenicity following a second year seasonal vaccination.
Vesikari T; Groth N; Karvonen A; Borkowski A; Pellegrini M
Vaccine; 2009 Oct; 27(45):6291-5. PubMed ID: 19840662
[TBL] [Abstract][Full Text] [Related]
7. Combined, concurrent, and sequential administration of seasonal influenza and MF59-adjuvanted A/H5N1 vaccines: a phase II randomized, controlled trial of immunogenicity and safety in healthy adults.
Lopez P; Caicedo Y; Sierra A; Tilman S; Banzhoff A; Clemens R
J Infect Dis; 2011 Jun; 203(12):1719-28. PubMed ID: 21606530
[TBL] [Abstract][Full Text] [Related]
8. MF59™ as a vaccine adjuvant: a review of safety and immunogenicity.
El Sahly H
Expert Rev Vaccines; 2010 Oct; 9(10):1135-41. PubMed ID: 20923265
[TBL] [Abstract][Full Text] [Related]
9. Antibody and T-cell responses to a virosomal adjuvanted H9N2 avian influenza vaccine: impact of distinct additional adjuvants.
Radosević K; Rodriguez A; Mintardjo R; Tax D; Bengtsson KL; Thompson C; Zambon M; Weverling GJ; Uytdehaag F; Goudsmit J
Vaccine; 2008 Jul; 26(29-30):3640-6. PubMed ID: 18514980
[TBL] [Abstract][Full Text] [Related]
10. Vaccines with MF59 adjuvant expand the antibody repertoire to target protective sites of pandemic avian H5N1 influenza virus.
Khurana S; Chearwae W; Castellino F; Manischewitz J; King LR; Honorkiewicz A; Rock MT; Edwards KM; Del Giudice G; Rappuoli R; Golding H
Sci Transl Med; 2010 Jan; 2(15):15ra5. PubMed ID: 20371470
[TBL] [Abstract][Full Text] [Related]
11. MF59-adjuvanted influenza vaccine confers superior immunogenicity in adult subjects (18-60 years of age) with chronic diseases who are at risk of post-influenza complications.
Baldo V; Baldovin T; Floreani A; Carraro AM; Trivello R;
Vaccine; 2007 May; 25(20):3955-61. PubMed ID: 17383057
[TBL] [Abstract][Full Text] [Related]
12. Cross-protection by MF59-adjuvanted influenza vaccine: neutralizing and haemagglutination-inhibiting antibody activity against A(H3N2) drifted influenza viruses.
Ansaldi F; Bacilieri S; Durando P; Sticchi L; Valle L; Montomoli E; Icardi G; Gasparini R; Crovari P
Vaccine; 2008 Mar; 26(12):1525-9. PubMed ID: 18294741
[TBL] [Abstract][Full Text] [Related]
13. The adjuvant effect of MF59 is due to the oil-in-water emulsion formulation, none of the individual components induce a comparable adjuvant effect.
Calabro S; Tritto E; Pezzotti A; Taccone M; Muzzi A; Bertholet S; De Gregorio E; O'Hagan DT; Baudner B; Seubert A
Vaccine; 2013 Jul; 31(33):3363-9. PubMed ID: 23684834
[TBL] [Abstract][Full Text] [Related]
14. Monitoring the effects of component structure and source on formulation stability and adjuvant activity of oil-in-water emulsions.
Fox CB; Anderson RC; Dutill TS; Goto Y; Reed SG; Vedvick TS
Colloids Surf B Biointerfaces; 2008 Aug; 65(1):98-105. PubMed ID: 18440205
[TBL] [Abstract][Full Text] [Related]
15. Vaccine adjuvant activity of emulsified oils from species of the Pinaceae family.
Fox CB; Van Hoeven N; Granger B; Lin S; Guderian JA; Hartwig A; Marlenee N; Bowen RA; Soultanov V; Carter D
Phytomedicine; 2019 Nov; 64():152927. PubMed ID: 31465981
[TBL] [Abstract][Full Text] [Related]
16. MF59 Mediates Its B Cell Adjuvanticity by Promoting T Follicular Helper Cells and Thus Germinal Center Responses in Adult and Early Life.
Mastelic Gavillet B; Eberhardt CS; Auderset F; Castellino F; Seubert A; Tregoning JS; Lambert PH; de Gregorio E; Del Giudice G; Siegrist CA
J Immunol; 2015 May; 194(10):4836-45. PubMed ID: 25870238
[TBL] [Abstract][Full Text] [Related]
17. Development of a novel oil-in-water emulsion and evaluation of its potential adjuvant function in a swine influenza vaccine in mice.
Zhang J; Miao J; Han X; Lu Y; Deng B; Lv F; Zhao Y; Ding C; Hou J
BMC Vet Res; 2018 Dec; 14(1):415. PubMed ID: 30577861
[TBL] [Abstract][Full Text] [Related]
18. Cross-reactive antibodies in middle-aged and elderly volunteers after MF59-adjuvanted subunit trivalent influenza vaccine against B viruses of the B/Victoria or B/Yamagata lineages.
Camilloni B; Neri M; Lepri E; Iorio AM
Vaccine; 2009 Jun; 27(31):4099-103. PubMed ID: 19410623
[TBL] [Abstract][Full Text] [Related]
19. Enhanced immunogenicity of seasonal influenza vaccines in young children using MF59 adjuvant.
Vesikari T; Pellegrini M; Karvonen A; Groth N; Borkowski A; O'Hagan DT; Podda A
Pediatr Infect Dis J; 2009 Jul; 28(7):563-71. PubMed ID: 19561422
[TBL] [Abstract][Full Text] [Related]
20. Immune response to influenza A (H1N1)v monovalent MF59-adjuvanted vaccine in HIV-infected patients.
Fabbiani M; Di Giambenedetto S; Sali M; Farina S; Sansonetti P; Tamburrini E; Dal Verme LZ; Delogu G; De Luca A; Kelvin D; Cauda R; Fadda G
Vaccine; 2011 Apr; 29(16):2836-9. PubMed ID: 21349364
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
